In May 14 and 21 letters to FDA Com.-designate Young, Rep. Weiss (D-NY) asks FDA to identify "all 'new drugs' currently on the market which are not the subject of an approved" NDA or ANDA. Agency is to note date of initial marketing, distributors and mfrs., whether the drug is listed in the 1984 PDR, adverse reactions associated with its use and "the specific legal basis for permitting its continued marketing." Weiss also asks for "an explanation of FDA's regulatory requirements for reporting serious adverse effects associated with the use of the above-listed drugs".
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.